Drugs / IPX159
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01521663 | Nov 2011 → Feb 2013 | restless legs syndrome | Impax Laboratories, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-05-10 | Impax Laboratories, LLC | Regulatory Impax Pharmaceuticals Provides an Update on Pipeline Candidate IPX159 amneal.com ↗
Impax Pharmaceuticals,the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced the successful filing of an Investigational New Drug Application (IND) for IPX159 in Restless Legs Syndrome (RLS) and initiated a Phase I study. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-12-19 | Impax Laboratories, LLC | Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome amneal.com ↗ |
| 2011-05-10 | Impax Laboratories, LLC | Impax Pharmaceuticals Provides an Update on Pipeline Candidate IPX159 amneal.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPX159 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01521663 ↗ |